Innate Pharma Files 6-K, Names New CEO
Ticker: IPHYF · Form: 6-K · Filed: Oct 29, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, leadership-change, foreign-private-issuer
Related Tickers: IPHA
TL;DR
Innate Pharma filed a 6-K, new CEO Johnathan Dickinson is in, and they're sticking with the 20-F for annual reports.
AI Summary
Innate Pharma S.A. filed a Form 6-K on October 29, 2024, reporting information as of that date. The filing includes details about the company's principal executive office in Marseille, France, and confirms it files annual reports under Form 20-F. It also references Exhibit 99.1, which contains statements from Irina Staatz-Granzer and Johnathan Dickinson, the new CEO and Chairman.
Why It Matters
This filing provides an update on Innate Pharma's corporate structure and leadership, including the appointment of a new CEO and Chairman, which could signal strategic shifts for the company.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate information and leadership updates, with no immediate financial or operational risks indicated.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- October 29, 2024 (date) — Filing date
- Marseille, France (location) — Principal executive office
- Form 20-F (document) — Annual report form
- Irina Staatz-Granzer (person) — Chairwoman of the Supervisory Board
- Johnathan Dickinson (person) — Appointed Chief Executive Officer and Chairman of the Executive Board
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer, providing information as of October 29, 2024, and referencing Exhibit 99.1 which includes statements from company leadership.
Who has been appointed as the new Chief Executive Officer and Chairman of Innate Pharma S.A.?
Johnathan Dickinson has been appointed as the Chief Executive Officer and Chairman of the Executive Board of Innate Pharma S.A.
What is the company's principal executive office address?
The company's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma file its annual reports under Form 20-F or 40-F?
Innate Pharma files its annual reports under cover of Form 20-F.
Who is the Chairwoman of the Supervisory Board of Innate Pharma S.A. mentioned in the filing?
Irina Staatz-Granzer is mentioned as the Chairwoman of the Supervisory Board of Innate Pharma S.A.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-10-29 07:03:24
Filing Documents
- a6k-iphx241029.htm (6-K) — 11KB
- exhibit991-2410141.htm (EX-99.1) — 16KB
- 0001598599-24-000078.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date October 29, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer